NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

The Schall Law Firm reminds investors of a class action lawsuit against Nektar Therapeutics for securities fraud violations.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Nektar Therapeutics (NASDAQ: NKTR) for violations of the Securities Exchange Act of 1934. Investors who purchased the company's securities between February 26, 2025 and December 15, 2025 are encouraged to contact the firm before the May 5, 2026 deadline to participate in the lawsuit.

Why it matters

This lawsuit alleges that Nektar Therapeutics made false and misleading statements to the market regarding the enrollment and integrity of its REZOLVE-AA clinical trial for its product candidate rezpegaldesleukin. If the allegations are proven true, it could result in significant financial damages for investors who suffered losses.

The details

According to the complaint, Nektar's enrollment of patients for the REZOLVE-AA trial failed to follow protocol standards, and the company's enrollment problems were likely to have a negative impact on the trial's findings. The company is accused of overstating the integrity of its REZOLVE-AA trial, leading to false and materially misleading public statements during the class period.

  • The class period is from February 26, 2025 to December 15, 2025.
  • The deadline for investors to join the lawsuit is May 5, 2026.

The players

Nektar Therapeutics

A biopharmaceutical company that develops innovative medicines based on its proprietary polymer conjugate technology platform.

The Schall Law Firm

A national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm (Business Wire)

What’s next

The judge will decide on May 5, 2026 whether to certify the class in this securities fraud lawsuit against Nektar Therapeutics.

The takeaway

This case highlights the importance of transparency and accurate reporting by pharmaceutical companies, especially when it comes to clinical trials that can significantly impact investor confidence and stock prices. Investors who suffered losses due to Nektar's alleged misconduct may have the opportunity to recover those losses through this class action lawsuit.